| Ident. | Authors (with country if any) | Title |
|---|
| 000106 |
P. Peran [France, Italie] ; F. Nemmi [Italie] ; D. Meligne [France] ; D. Cardebat [France] ; A. Peppe [Italie] ; O. Rascol [France] ; C. Caltagirone [Italie] ; J. F. Demonet [Suisse] ; U. Sabatini [Italie] | Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study |
| 000667 |
O. Rascol [France] | Thérapeutiques du stade précoce de la maladie de Parkinson |
| 000828 |
T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien |
| 000882 |
A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | Levodopa raises objective pain threshold in Parkinson's disease : a Rill reflex study |
| 000A97 |
Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne] | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary |
| 000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
| 001078 |
S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France] | Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease |
| 001176 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease |
| 001196 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
| 001330 |
O. Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
| 001345 |
E. Bezard [France] ; C. Brefel [France] ; F. Tison [France] ; H. Peyro-Saint-Paul [France] ; P. Ladure [France] ; O. Rascol [France] ; C. E. Gross [France] | Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in mptp-treated monkey |
| 001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
| 001386 |
O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France] | Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens |
| 001407 |
C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France] | α2-Adrenoceptor antagonists: A new approach to Parkinson's disease? |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001461 |
O. Rascol [France] ; U. Sabatini [France, Italie] ; C. Brefel [France] ; N. Fabre [France] ; S. Rai [France] ; J. M. Senard [France] ; P. Celsis [France] ; G. Viallard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia |
| 001523 |
O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France] | Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie |
| 001672 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
| 001791 |
O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; P. Calsis [France] ; J. P. Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa |
| 001816 |
J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] ; A. Rascol | A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up |
| 001A43 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
| 001B01 |
O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. Rascol | Abnormal ocular movements in Parkinson's disease: evidence for involvement of dopaminergic systems |
| 001B17 |
J.-P. Marc-Vergnes ; P. Celsis ; J. L. Montastruc ; J. F. Demonet ; A. Agniel ; O. Rascol ; G. Viallard ; B. Doyon ; A. Rascol | Hémodynamique cérébrale et pharmacologie clinique dans la maladie de Parkinson |
| 001B20 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Bromocriptine versus levodopa dans le traitement de première intention de la maladie de Parkinson. Premiers résultats à deux ans |
